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27Objective: Oxidative stress has been linked to osteoporosis. Serum uric acid (UA), a strong endogenous anti-
28oxidant, has been associated with higher bone mineral density (BMD), lower bone turnover and lower prev-
29alence of fractures in a large cross-sectional study of men. Whether this relationship is present in women and
30how UA relates to changes in BMD longitudinally has not been examined.
31Methods: A sample of 356 peri- and postmenopausal women, mean age 60.5 years was studied. Each individ-
32ual had baseline BMD and body composition measurements by dual energy x-ray absorptiometry (DXA) and
33at least one repeat measure, on average 9.7 years later. Annual rate of change in BMD (A%ΔBMD) was calcu-
34lated. UA was measured at each DXA visit. Calciotropic hormones and bone turnover markers were measured
35at the ﬁnal visit only.
36Results: Cross-sectional data analyses revealed that women with higher UA levels had signiﬁcantly higher
37absolute BMD measures at all skeletal sites. These women also had higher measures of body weight and its
38components such as lean mass (LM) and fat mass (FM). Results of multiple regression analyses showed a
39positive association between UA and BMD that remained signiﬁcant even after accounting for possible con-
40founders including LM and FM. Regression analyses of the longitudinal BMD data demonstrated signiﬁcant
41associations between serum UA levels and annual rates of change in BMD at all skeletal sites. After adjust-
42ment associations remained signiﬁcant for lumbar spine, forearm and whole body BMD but not for hip BMD.
43Conclusion: Higher serum UA levels appear to be protective for bone loss in peri- and postmenopausal women
44and this relationship is not affected by changes in body composition measures.
45© 2012 Published by Elsevier Inc.
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50 Introduction
51 Soluble uric acid (UA) is present principally as monosodium urate
52 at physiological pH values and is the ﬁnal breakdown product of
53 purine metabolism. Historically, UA has been viewed as a waste
54 byproduct, which in excess may cause gouty arthritis and renal stones
55 [1,2]. While it is well recognised that UA in its crystalline state is
56 pro-inﬂammatory [3], there has been controversy as to the biological
57 roles of soluble UA. Although soluble UA was considered biologically
58 relatively inert, it is now thought that higher serum UA levels within
59 normal physiologic levels (0.15–0.4 mmol/L) [4] may have conferred
60 a selection advantage because of their antioxidant effects [3,5–7].
61 Indeed, UA accounts for approximately half of the antioxidant
62 properties of human plasma [3]. Evidence from observational and
63epidemiological studies has linked oxidative stress or low circulating
64levels of anti-oxidants to reduced bonemineral density (BMD) and oste-
65oporosis [8–11]. On the other hand, increased body weight has been
66reported as one of the major predictors of elevated levels of serum UA
67[3,12]. Supranormal serumUA levels (hyperuricaemia) have been associ-
68ated with presence of the metabolic syndrome [7,12–15] and its compo-
69nents such as diabetes mellitus [16,17], obesity [18–20], hyperlipidemia
70[21–23] and hypertension [19,24]. Body weight has been related to
71BMD [25–27]. Numerous previous studies have also reported positive
72associations between body composition components such as lean body
73mass and fat body mass and BMD at different skeletal sites [27–30].
74In a large population-based study of older men (the CHAMP Study),
75the CHAMP collaborative recently reported that higher serumUA levels
76were signiﬁcantly associated with higher BMD at various skeletal sites
77after adjusting for covariates [31]. Moreover, higher serum UA levels
78were associated with a lower prevalence of osteoporosis as determined
79by either BMD or prevalent non-vertebral fracture status. Whether this
80relationship is present inwomen and howUA relates to changes in BMD
81longitudinally has not been examined.
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82 Methods
83 Subjects
84 Study subjects were female twins over 45 years, recruited as part
85 of the Northern Sydney Twin Study, which has been running at the
86 Department of Rheumatology, Royal North Shore Hospital, since
87 1996. The twins were recruited through the Australian National
88 Health and Medical Research Council (NHMRC) Twin Registry and
89 from local media campaigns. Twins were invited to participate in an
90 investigation into the genetic and environmental determinants of
91 various diseases including osteoarthritis, cardiovascular disease, asth-
92 ma, and osteoporosis on several occasions. The hospital's Human
93 Research Ethics Committee approved the study. After providing writ-
94 ten informed consent, each twin was interviewed separately in accor-
95 dance with a standard questionnaire to collect demographic, lifestyle
96 and medical history data. The baseline visit was completed by 1980
97 twins (1997–2006), and 864 of these participants attended at least
98 one follow-up visit (2009–2010).
99 Except for hormone therapy, twins who used medications or who
100 had medical conditions that could interfere with bone metabolism
101 were excluded from the analysis. Individuals with conditions that
102 might compromise the accuracy of DXAmeasurements such as severe
103 obesity, the presence of artiﬁcial objects such as pacemaker or gall-
104 stones, or signiﬁcant degenerative spine changes were also excluded.
105 Hormone therapy use was recorded and included as a covariate in the
106 statistical analyses. Zygosity in same-sex twins was determined from
107 the twins' self-report using questions from a validated questionnaire
108 [32]. DNA ﬁngerprinting was used to determine zygosity in twin pairs
109 in which their zygosity was either unknown or disputed.
110 Baseline characteristics and laboratory measurements
111 Demographic characteristics of the study cohort included age
112 (years), height (m), weight (kg), BMI (kg/m2), menopausal status
113 (MS), hormone replacement therapy (HRT), physical activity (PA),
114 alcohol intake and smoking history. Menopausal status was
115 categorised as 1 — premenopausal (i.e. having regular menstrual
116 cycles), 2— perimenopausal (i.e. experiencing changes in frequency
117 of their menses or amenorrhoea of at least 3 but less than 12 months)
118 and 3 — postmenopausal (amenorrhoea for 12 consecutive months).
119 Hormone replacement therapy was recorded and accounted for if
120 taken regularly for more than 3 months within the last 12 months. PA
121 was categorised based on time spent on leisure exercise for>
122 30 minutes per day (0 — none, 1 — b30 min/day, 2 — ≥30 min/day).
123 Alcohol intake was recorded as standard drinks per week and
124 categorised as 0 — none; 1 —≤1 drink per week (social occasions
125 only); 2 — 2–13 drinks per week (moderate) and 3—≥14 drinks
126 per week (excessive). Smoking habits were recorded as 0 — never;
127 1— current smoker; 2— ex-smoker (not smoked in the last 3 months).
128 Self-reported fractures that occurred between baseline and the ﬁnal
129 visits of the study were also recorded.
130 Fasting blood samples used in this study were collected at each
131 subject's visit and kept as aliquots at −80° C until analysis. Serum
132 UA was measured from baseline and last visit blood samples. Other
133 biochemical parameters such as creatinine, calcium, albumin and
134 phosphorus and bone markers were measured from the last visit
135 samples only. These tests were performed using standard techniques
136 on a Roche Modular AnalyticsbP>module (Roche Diagnostics,
137 Germany). The UA assay had a detection limit of 0.01 mmol/L, female
138 reference range of 0.18–0.38 mmol/L and combined measurement
139 of uncertainty of 1.1% at 0.18 and 0.44 mmol/L. Serum calcium was
140 measured by colorimetric assay using p-cresolphthalein. Values
141 were adjusted for circulating albumin levels with a reference
142 range of 2.15–2.5 mmol/L. Glomerular ﬁltration rate (GFR) was calcu-
143 lated using the Cockroft–Gault formula [33,34]. Serum levels of
144aminoterminal procollagen type I propeptide (PINP) were deter-
145mined by Electrochemiluminescence immunoassay on a Roche Mod-
146ular Analytics E170 module (Roche Diagnostics GmbH, Germany).
147The assay for serum PINP, a marker of bone formation, detects both
148trimeric and monomeric fractions of PINP. The detection limit was
1495 ng/mL with total precision coefﬁcients of variation (CVs) of be-
150tween 3.8% and 4.2%. Serum concentrations of the aminoterminal
151cross-linked telopeptide of collagen type I (Serum CTX-I) were mea-
152sured using a manual immunoassay (Osteomark, Ostex, USA).
153Bone Mineral Density and Body Composition Measurements
154Lumbar spine (LS), total hip, forearm and whole body scans were
155performed on a fan beam dual-energy X-ray absorptiometry (DXA)
156bone densitometer (QDR 4500W, Hologic, Waltham, MA USA) at
157baseline and follow-up visits. Measurements of bone mineral density
158(BMD) (g/cm2) and body composition such as fat mass (FM) (kg) and
159lean body mass (LM) (kg) were obtained using standard protocols as
160previously described [29,35]. The same densitometer was used
161throughout the entire study. Performance of the DXA scanner has
162been monitored throughout the study. Routine daily QC scans of the
163Spine Phantom were performed and the coefﬁcient of variation for
164QC BMD measures in our unit was 0.98%. In vivo reproducibility has
165been estimated from duplicate scans (155 patients with repositioning
166between scans) as coefﬁcients of variation (CV) and intraclass corre-
167lation (ICC) for BMD and body composition measures. CV and ICC
168for LS, total hip, femoral neck BMD were 0.74/0.998; 1.23/0.994
169and 1.27/0.994 correspondingly. CV and ICC for Total LM were 1.07/
1700.997 and for Total FM — 1.83/0.997.
171Baseline and last visit measurements were used to calculate an
172annual rate of change in BMD. Commonly accepted annual % change
173in BMD (%/year ΔBMD) was selected as a longitudinal BMD measure
174to adjust for difference in time between two end-point visits in
175study participants [36–41].
176Statistical analysis
177For comparison between groups of UA tertiles, ANOVA analysis for
178continuous variables and chi-square tests for categorical variables
179was performed. Adjusted means across tertiles of uric acid were also
180reported for bone-related and body composition measures at the
181ﬁnal visit. In addition, generalised linear regression models were
182used to assess the association between UA and BMD at the ﬁnal visit
183or annual rate of change in BMD (A%ΔBMD). Lack of independence
184of BMD measures between dizygotic (DZ) pairs was taken into
185account using generalised estimating equations. The annual rate
186of BMD change (A%ΔBMD) was calculated as 100×[BMD at ﬁnal
187visit−BMD at baseline]/BMD at baseline/ time interval between
188the two measurements, and was used to account for differences in
189the intervals among the study participants. The selection of this
190common parameter as the outcome variable for the longitudinal
191data was due to the fact that the vast majority of the participants
192had only two measurements.
193In multivariate regression analysis, BMD or A%ΔBMD were treated
194as dependent variables, and log UA or A%ΔUA as independent vari-
195ables. Models were adjusted for known and potential confounders,
196including GFR, serum calcium and CTX-I levels, age, history of
197smoking, alcohol intake, HRT use and physical activity. We did not in-
198clude weight or BMI in models because weight is made up of BMC,
199lean mass and fat mass. We included both lean mass and fat mass
200and height as a correction for body size in ﬁnal models. Regression
201analyses for relationships between UA and body composition mea-
202sures were done in a similar manner by treating one of the body com-
203position measures as dependent variable in the regression models.
204Longitudinal data was also analysed by time dependent mixed regres-
205sion models.
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206 Results
207 There were 460 female twin participants who had completed their
208 last follow-up visit: 96 monozygotic (MZ) and 134 dizygotic (DZ)
209 pairs. After randomly excluding one member of each MZ twin pair
210 (n=96) and subjects taking allopurinol (n=4), thiazides (n=2) or
211 loop diuretics (n=2), 356 women with a mean age of 60.4 (range
212 45–83) years remained for analysis.
213 Cross-sectional analyses
214 Themain anthropometric, biochemical and lifestyle characteristics
215 of these subjects at the ﬁnal visit, stratiﬁed by tertiles of UA levels are
216 presented in Table 1. There were 26 hyperuricemic women (serum
217 UA levels ≥0.41 mmol/L) in the highest tertile of UA. As expected
218 ﬁnal visit UA levels were higher than baseline levels. Women with
219 higher serum UA levels were older, heavier and correspondingly
220 had higher BMI than those with lower UA concentrations. Total
221 serum cholesterol, LDLC, triglyceride, calcium and creatinine levels
222 were all signiﬁcantly higher in the higher UA tertiles. Serum CTX-I
223 levels were higher in the highest UA tertile, but no between-tertile
224 differences were seen for any of the other bone-related biochemical
225 parameters. There was no signiﬁcant difference in history of smoking,
226 alcohol intake or physical activity between groups. There were 40
227 incident self-reported fractures during the follow-up period with no
228 apparent difference in fracture rates between UA tertiles.
229Crude bone density measures of the study cohort at the ﬁnal visit
230are shown in Table 2a. When analysed by tertile of serum UA, women
231with higher UA levels had signiﬁcantly higher absolute BMD at all
232skeletal sites at baseline (data not shown) and follow-up visits. Ad-
233justed means for ﬁnal visit bone density measures at different skeletal
234sites across tertiles of UA are presented in Fig. 1. Unadjusted body
235composition measures of the study cohort at the ﬁnal visit are
236shown in Table 2b. Both body fat and lean mass measures as well as
237the body fat to lean mass ratio were signiﬁcantly higher in the medi-
238um and high UA group. Similar results were obtained for baseline
239body composition characteristics (data not shown). Adjusted means
240for the ﬁnal visit body weight, lean mass and fat mass measures
241across tertiles of UA are presented in Fig. 2.
242Multiple regression analysis was performed to examine the
243cross-sectional associations between serum uric acid levels and ﬁnal
244visit BMD measures at different skeletal sites. Estimates of the fully
245adjusted regression models are presented in Table 3. Serum UA levels
246were positively associated with baseline and ﬁnal visit cross-sectional
247bone density measures at all skeletal sites after adjustment for GFR,
248serum Ca and CTX-I levels, age, FM/LM/Ht2, smoking, alcohol, HRT
249use and physical activity.
250Longitudinal analyses
251Mean duration of follow-up was 9.7±1.8 years and did not differ
252between UA tertiles. Longitudinal bone density and body composition
Table 1t1:1
t1:2 Demographic, biochemical and lifestyle characteristics of the study subjects at ﬁnal visit stratiﬁed by tertiles of serum uric acid levels (Final Visit).a
t1:3 Tertiles of uric acid levels
t1:4 All 1 2 3 Sig.
t1:5 (N=356) (N=122) (N=106) (N=128)
t1:6 Mean±SD Mean±SD Mean±SD Mean±SD
t1:7 Age (years) 60.44±7.89 59.23±7.88 60.47±8.30 61.57±7.43 0.019⁎
t1:8 Duration of Follow-Up (years) 9.68±1.84 9.87±1.51 9.45±2.09 9.69±1.89 0.450
t1:9 Weight (kg) 69.44±12.36 63.58±9.61 70.63±13.06 74.00±11.88 b0.000§
t1:10 Height (m) 1.61±0.06 1.61±0.06 1.62±0.06 1.60±0.06 0.190
t1:11 BMI (kg/m2) 26.83±4.92 24.48±3.83 27.09±5.19 28.85±4.68 b0.000§
t1:12 Biochemistry measures:
t1:13 Uric Acid Baseline Visit (mmol/L) 0.26±0.06 0.22±0.05 0.25±0.05 0.30±0.05 b0.000§
t1:14 Uric Acid Final Visit (mmol/L) 0.29±0.07 0.21±0.04 0.28±0.01 0.36±0.05 b0.000§
t1:15 A%ΔChange in Uric Acid (% per yr) 1.36±3.16 0.26±3.84 1.59±2.37 2.36±2.67 b0.000§
t1:16 Total Cholesterol (mmol/L) 5.47±0.96 5.41±0.92 5.33±0.93 5.63±1.01 0.060
t1:17 HDLC (mmol/L) 1.45±0.38 1.50±0.42 1.45±0.36 1.41±0.36 0.053
t1:18 LDLC (mmol/L) 3.39±1.02 3.21±1.17 3.30±0.87 3.63±0.94 0.001±
t1:19 Triglycerides 1.20±0.60 1.08±0.41 1.19±0.72 1.31±0.63 0.003±
t1:20 Calcium (mmol/L) 2.30±0.09 2.28±0.09 2.30±0.09 2.32±0.09 b0.000§
t1:21 Creatinine (micromol/L) 68.99±11.06 65.48±9.14 68.45±9.29 72.79±12.82 b0.000§
t1:22 C-Reactive Protein (nmol/L) 2.80±3.65 2.28±3.94 2.79±3.74 3.30±3.22 0.027⁎
t1:23 Serum CTX-I (μg/L) 283.97±157.86 260.71±142.58 290.35±157.08 300.67±170.37 0.047⁎
t1:24 PINP (μg/L) 46.14±20.20 46.82±20.39 47.10±20.13 44.73±20.17 0.410
t1:25 GFR 85.53±22.84 83.26±18.58 88.26±27.44 85.44±22.26 0.466
t1:26 Fractures: 39 (11.0%) 12 (9.8%) 16 (15.1%) 11 (8.6%) 0.200
t1:27 Lifestyle characteristics:
t1:28 Smoking History: (N (%)) 0.620
t1:29 Never 224 (62.9%) 72 (59.0%) 72 (67.9%) 80 (62.5%)
t1:30 Current 21 (6.9%) 7 (5.7%) 7 (6.6%) 7 (5.5%)
t1:31 Ex-smoker 111 (31.2%) 43 (35.2%) 27 (25.5%) 41 (32.0%)
t1:32 Alcohol intake (N(%)) 0.411
t1:33 ≤ 1 drink per week 142 (39.9%) 50 (41.0%) 43 (40.6%) 49 (38.3%)
t1:34 2–14 drinks per week 207 (58.1%) 71 (58.2%) 62 (58.5%) 74 (57.8%)
t1:35 ≥ Drinks 14 per week 7 (2.0%) 1 (0.8%) 1 (0.9%) 5 (3.9%)
t1:36 Physical activity (N (%)) 0.788
t1:37 None 18 (5.1%) 4 (3.3%) 7 (6.6%) 7 (5.5%)
t1:38 b 30 min per day 167 (46.9%) 58 (47.5%) 47 (44.3%) 62 (48.4%)
t1:39 ≥ 30 min per day 171 (48.0%) 62 (50.8%) 50 (47.2%) 59 (46.1Q2 %)
a ANOVA and test of linearity were performed.t1:40
⁎ pb0.05.t1:41
± pb0.01.t1:42
§ pb0.001.t1:43
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253 measures of the study cohort stratiﬁed by tertiles of UA are shown in
254 Tables 2a and 2b. Annual rates of increase in body weight and lean
255 body mass (LM) over the preceding 9 years were signiﬁcantly related
256 to higher serum UA levels and these associations remained after
257 adjusting for potential confounders: age, height, history of smoking,
258 alcohol intake, HRT use and physical activity (data not shown).
259 There was a general trend for women in the highest tertile of UA to
260 be losing bone at a slower rate than those with lower UA level. How-
261 ever this relationship was statistically signiﬁcant only for A%ΔLSBMD.
262 Women in the highest UA tertile had gained more weight and more
263 lean mass over time, but changes in fat mass were not signiﬁcantly
264 different by UA tertiles (Fig. 2).
265 Multiple regression analyses were performed to examine the asso-
266 ciations between serum UA and longitudinal BMD measures at differ-
267 ent skeletal sites (Table 4). Higher rates of annual change in UA levels
268 were associated with slower rate of decline in BMD at all skeletal
269 sites. When the regression models were adjusted for A%ΔFM (model
270 2) or A%ΔLM (model 3), the associations between change in UA levels
271 and change in BMD measures remained signiﬁcant at the spine only.
272 The results of the time dependent mixed model regression analy-
273 ses conﬁrmed these ﬁndings (not shown).
274Discussion
275In a previous cross-sectional study [31] the CHAMP consortium has
276reported that higher serum UA levels are associated with greater BMD
277at all skeletal sites in an older male population. In the present study,
278wehave conﬁrmed, for theﬁrst time, that a similar relationship exists be-
279tween serumUA and BMD in peri- and postmenopausalwomen. In addi-
280tion, we have shown that serum UA is also associated with the rate of
281change in BMD over time in women. In the lumbar spine, forearm and
282total body, those with higher UA levels were relatively protected from
283bone loss compared to those with lower levels. However the protective
284effect of UA on longitudinal BMD appeared to be weaker at hip sites.
285Body weight is well known to be related to BMD [27]. However,
286there has been considerable controversy about the association
287between fat body mass and lean body mass and their relationship to
288BMD [27,28,30]. Gender and age are likely to be important factors
289in modifying this relationship given we showed previously in a
290cross-sectional study of opposite sex twins that lean mass had stron-
291ger relationships with most bone variables than fat mass in both gen-
292ders at all ages, but fat mass had a positive relationship with total
293body and hip BMD in women under 50 and men over 50 years of
294age [29]. Body weight and in particular obesity are also associated
295with serum UA levels [12,20,42]. In the present study, UA was also
296associated with cross-sectional weight, FM and LM measures and
297the rate of change over time in lean body mass. Those women with
298high UA levels gained more lean body mass without much change
299in fat mass. However after adjusting for lean mass or fat mass, the
300relationship between UA and BMD remained.
301As noted above, UA is the end product of purine metabolism
302which in turn is related to lean body mass. However our analyses of
303changes in body composition do not explain the relationship ob-
304served between serum UA and cross-sectional or longitudinal BMD.
305We found modestly higher serum CTX-I values in women in the
306highest tertile of UA, which might be expected to be associated with
307increased bone loss over time rather than what was actually ob-
308served. Taken together, these longitudinal data suggest that the rela-
309tionship between serum UA and lumbar spine BMD in women, both
310cross-sectionally and longitudinally, is not mediated to any great
311extent by the relationship between body composition and UA or by
312direct effects on bone remodeling. Evidence from observational and
313epidemiological studies has linked oxidative stress to reduced BMD
314and osteoporosis [9–11] and since UA accounts for approximately
Table 2at2:1
t2:2 Cross-sectional (ﬁnal visit) and longitudinal bone mineral density measures of the study subjects, stratiﬁed by tertiles of serum uric acid levels.a
t2:3 Tertiles of uric acid
t2:4 All 1 2 3 Sig.
t2:5 (N=356) (N=122) (N=106) (N=128)
t2:6 Mean±SD Mean±SD Mean±SD Mean±SD
t2:7 Cross-sectional BMD (g/cm2)
t2:8 Lumbar spine 0.952±0.158 0.923±0.157 0.949±0.148 0.982±0.164 0.003±
t2:9 Femoral neck 0.751±0.120 0.726±0.111 0.761±0.112 0.767±0.132 0.007±
t2:10 Hip total 0.896±0.125 0.869±0.123 0.907±0.119 0.914±0.129 0.005±
t2:11 Forearm total 0.522±0.058 0.511±0.061 0.527±0.054 0.528±0.057 0.022⁎
t2:12 Whole body total 1.089±0.116 1.071±0.116 1.091±0.120 1.105±0.113 0.021⁎
t2:13
t2:14 A%ΔChange in BMD (% per year)
t2:15 Lumbar spine −0.50±0.83 −0.58±0.85 −0.57±0.76 −0.37±0.86 0.044⁎
t2:16 Femoral neck −0.45±0.75 −0.46±0.76 −0.45±0.78 −0.44±0.72 0.794§Q3
t2:17 Hip total −0.38±0.61 −0.39±0.67 −0.39±0.52 −0.36±0.61 0.636
t2:18 Forearm total −0.62±0.58 −0.62±0.62 −0.66±0.61 −0.59±0.52 0.630
t2:19 Whole body total −0.21±0.65 −0.25±0.67 −0.24±0.62 −0.14±0.65 0.200
a ANOVA and test of linearity were performed.t2:20
⁎ pb0.05.t2:21
± pb0.01.t2:22
§ pb0.001.t2:23
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Fig. 1. Adjusted means of Lumbar Spine, Femoral Neck, Total Hip and Whole Body
cross-sectional BMD measures (ﬁnal visit) across tertiles of Serum Uric Acid
(N=356)*. * BMD means adjusted for GFR, serum Ca and CTX-I levels, age, height; his-
tory of smoking, history alcohol intake, history HRT use and physical activity.
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315 half of the antioxidant properties of human plasma [3], this mecha-
316 nism of action as an explanation of our ﬁndings requires further
317 investigation. The lesser protective effect of UA on hip BMD in our
318 longitudinal analyses may reﬂect that hip BMD is more inﬂuenced
319by body composition measures [43,44] and local environmental
320factors such as weight bearing and also deserves further study.
321Although we have demonstrated that higher serum UA values are
322associated with higher BMD and lower rates of bone loss in women,
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Fig. 2. Adjusted means of body weight and body composition measures across tertiles of uric acid*. *Means adjusted for UA, GFR, serum Ca and CTX-I levels, age, height; history of
smoking, history alcohol intake, history of HRT use and physical activity.
Table 2bt3:1
t3:2 Cross-sectional (ﬁnal visit) and Longitudinal Body composition measures of the study subjects, stratiﬁed by tertiles of serum uric acid levels.a
t3:3 Tertiles of uric acid
t3:4 All 1 2 3 Sig.
t3:5 (N=356) (N=122) (N=106) (N=128)
t3:6 Mean±SD Mean±SD Mean±SD Mean±SD
t3:7 Cross-sectional (kg):
t3:8 Whole body fat mass 23.84±7.88 20.11±6.05 24.44±8.30 26.87±7.68 b0.000§
t3:9 Whole body lean mass 40.07±5.55 38.30±4.30 40.34±6.75 41.51±5.06 b0.000§
t3:10 Fat mass/lean mass 0.59±0.16 0.52±0.14 0.59±0.15 0.64±0.16 b0.000§
t3:11 Longitudinal (% per year)
t3:12 A%Δ Whole body fat mass 0.09±2.09 0.09±2.06 0.07±2.20 0.11±2.03 0.947Q4 ±
t3:13 A%Δ Whole body lean mass 0.72±0.69 0.49±0.60 0.70±0.70 0.95±0.70 b0.000§
t3:14 A%Δ Fat mass /lean mass −0.57±2.00 −0.36±1.98 −0.58±2.08 −0.75±1.97 0.131Q5 ⁎
a ANOVA and test of linearity were performed.t3:15
⁎ pb0.05.t3:16
± pb0.01.t3:17
§ pb0.001.t3:18
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323 those with higher UA values also had a more adverse lipid proﬁle
324 with higher total cholesterol, lower LDLC and higher triglyceride
325 values and the clinical signiﬁcance of these opposing effects need fur-
326 ther evaluation. The existence of a possible link between bone, fat and
327 atherogenic pathways has been recognised for some time and serum
328 UA should now be added to consideration of any such interactions.
329 Previous studies in this regard are conﬂicting. Early postmenopausal
330 women with an atherogenic lipid proﬁle have been reported to
331 have lower lumbar and femoral neck BMD and an increased risk of
332 osteopaenia than those with a normal lipid proﬁle [45], which differs
333 from our ﬁndings. In a longitudinal study in postmenopausal women
334 aged 50–75 years, those with the largest increases in serum choles-
335 terol showed the greatest decreases in spine BMD independently of
336 change in the body mass index [46]. We have also previously reported
337 a modest inverse relationship between total serum cholesterol and
338 spine but not hip BMD in perimenopausal women [35], but none of
339 these studies considered the inﬂuence of serum UA.
340 Our study has a number of strengths. We measured change in
341 BMD and body composition measures in women over almost
342 10 years and UA levels at baseline and ﬁnal visits. For the ﬁrst time
343 the associations between serum UA and BMD and body composition
344 measured by DXA were studied on a relatively healthy population
345 of peri- and postmenopausal women. Our study also has some limita-
346 tions. Only UA levels were measured at the two end points of the
347 study. Bone markers or other biochemical characteristics were only
348measured at the ﬁnal visit. Whereas DXA is regarded by majority as
349a reference technique for the measurement of the bone mineral, fat
350and fat-free soft tissue compartments of the body, it is not without
351limitations. Several studies suggest that long term DXA precision
352results may be affected by substantial weight gain [47–50]. In our
353study subjects with severe obesity that affected the quality of DXA
354scans were excluded and regression analyses of the longitudinal
355BMD measures were adjusted for rates of changes in BMI.
356The variability in rates of change in BMD and body composition
357was high, although we measured change over almost 10 years and
358the changes we observed are consistent with annual rates of BMD
359change reported by others [51,52]. With only 40 incident fractures
360during the follow-up period we lacked power to examine the effect
361of UA on fractures.
362We recently reported that serum UA levels were signiﬁcantly
363associated with BMD at various skeletal sites after adjusting for covar-
364iates in a large population-based study of older men [30] and have
365now conﬁrmed a similar relationship exists in peri- and postmeno-
366pausal women.
367For decades it has been hypothesised that the antioxidant proper-
368ties of uric acid might be protective against aging, oxidative stress,
369and oxidative injury of cells, including cardiac, vascular, and neural
370cells. However, recent epidemiological and clinical evidences suggest
371that hyperuricaemia might be a risk factor for cardiovascular disease,
372where enhanced oxidative stress plays an important pathophysiolog-
373ical role. It has also been hypothesised that hyperuricaemia might be
374involved in chronic heart failure and metabolic syndrome [7,53,54].
375The apparent paradox between protective and toxic effects of UA
376is supported by clinical evidence that antioxidant compounds may
377become pro-oxidant compounds in certain situations, particularly
378when they are present in blood at abnormally high levels [7].
379The present study suggests that serum UA, when present at higher
380physiological concentrations, may have protective effects on BMD,
381most likely through its antioxidant properties. However, further
382studies are needed to establish the precise mechanism of action and
383whether serum UA plays a role in antagonising oxidative stress-
384induced bone loss.
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